Cipla gets four USFDA observations for three Goa facilities

0
378
cipla gets four usfda observations
cipla gets four usfda observations

Cipla gets four USFDA Observations. United States Food and Drug Administration (USFDA) has recently finished audit of three manufacturing facilities of Cipla in Goa.

However, the USFDA had issued four observations across these three facilities. The company in a filing to BSE released this information.

 On Friday, September 30, 2016, Cipla gets four USFDA Observations. United States Food and Drug Administration (USFDA) has recently finished audit of three manufacturing facilities of Cipla in Goa.

However, the USFDA had issued four observations across these three facilities. The company in a filing to BSE released this information.

The drug supplier giant, Cipla has confirmed that after the inspection US health regulator has issued four observations across its three manufacturing facilities in Goa.

United States Food and drug Administration has conducted audit recently, which was over yesterday. In this audit, USFDA issued four observations across these three facilities.

However, the company stated that these observations were primarily procedural in nature and the corporation has previously responded to the same.

Nevertheless, company has not yet revealed any detail of the observations. In contrast to the matter, company has also stated that the company operates its facilities with a high level of compliance and control.

Cipla gets four USFDA Observations – The stock was trading at Rs 581.55 in the afternoon trade on BSE, down 3.22 percent from its previous close.

 

LEAVE A REPLY